Profound Medical Announces Upcoming Financial Results
Profound Medical Corp. (NASDAQ: PROF), a forward-thinking medical device company, is preparing to announce its financial results for the second quarter of 2025. The announcement will occur after the stock market closes, providing insights into the company’s performance and growth trajectory.
Conference Call Scheduled for Key Updates
To discuss the financial outcomes and significant business developments during the quarter, Profound Medical will host a conference call. This event is set for 4:30 p.m. ET, offering an opportunity for stakeholders to engage with the management team.
Details of the Conference Call
Date: Thursday, August 14, 2025
Time: 4:30 p.m. ET
How to Participate: Interested participants can register for the live call. It will also be archived on the company's official website under the "Webcasts" section in the Investors area.
About Profound Medical Corp.
Profound Medical is dedicated to improving patient care through innovative, incision-free therapies designed for treating diseased tissue. One of their prominent technologies is TULSA-PRO®, a sophisticated system that integrates real-time MRI with AI-driven planning and temperature control. This cutting-edge approach aims to provide a minimally invasive treatment for various prostate conditions, including cancer and benign prostatic hyperplasia (BPH).
How TULSA-PRO® Works
The TULSA procedure employs real-time MR guidance to ensure precise targeting of prostate tissue while minimizing damage to surrounding areas. It operates via a single-session process that takes a few hours, offering patients a painless alternative to traditional surgery. As a result, recovery times are significantly reduced, allowing individuals to quickly return to their daily activities.
Expanding Therapeutic Options with Sonalleve®
In addition to TULSA-PRO®, Profound Medical is advancing its Sonalleve® platform, an innovative solution for treating uterine fibroids and managing palliative pain associated with bone metastases. This technology has recently gained approval in various markets, including significant recognition by regulatory authorities.
Future Prospects for Sonalleve®
Profound is in the initial stages of exploring further applications for Sonalleve®, including potential non-invasive ablation treatments for abdominal cancers. The clinical versatility of this platform promises to expand the company's reach and impact in the medical field.
Contact Profound Medical for More Information
If you have any questions or require more details, please don’t hesitate to reach out. Stephen Kilmer, from Investor Relations, is available to provide assistance.
Contact Information:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Frequently Asked Questions
What is Profound Medical known for?
Profound Medical specializes in developing incision-free therapies for treating diseased tissue, particularly in the area of prostate health.
When will Profound Medical announce its Q2 financial results?
The financial results will be announced on August 14, 2025, after market closure.
What is the TULSA-PRO® system?
The TULSA-PRO® is a medical device that uses MRI guidance and ultrasound technology to treat prostate conditions non-invasively.
Are there other technologies Profound Medical is working on?
Yes, alongside TULSA-PRO®, they are also commercializing the Sonalleve® platform for treating uterine fibroids and related conditions.
How can investors participate in the upcoming conference call?
Investors can register for the call via the company’s website and participate to hear more about the financial results and company updates.
